This handout file photo taken Sept. 2, 2014, provided by National Institute of Allergy and Infectious Diseases (NIAID) shows a 39-year-old woman, the first participant enrolled in VRC 207, receiving a dose of the investigational NIAID/GSK Ebola vaccine at the National Institute of Health (NIH) Clinical Center in Bethesda, Md. (AP Photo/NIAID, File)